Associate Professor, Comprehensive Cancer Center, Yale University School of Medicine
Hematology
Dr. Scott N. Gettinger, MD
|
|
Give Review
Doctor Scott N. Gettinger, MD practices Hematology. He studied medicine at State University of New York Downstate Medical Center College of Medicine. He over the years received 2 awards: "Top Doctors: New York Metro Area" and "CMS Meaningful Use Stage 1 Certification". Scott Gettinger is a published doctor as well. He has 34 publications published. The latest was: An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial. Scott Gettinger accepts Medicare payments and is listed with Medicare.gov.
Publications
- An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial.
- Precipitation of AutoImmune Diabetes With Anti-PD-1 Immunotherapy.
- Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid Tumors.
- Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo.
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in Cancer patients.
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations.
- Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer.
- Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1.
- Programmed death ligand-1 expression in non-small cell lung Cancer.
- A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-Small Cell Lung Cancer.
- SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung Cancer.
- Treatment of stage IV non-small cell lung Cancer: Diagnosis and management of lung Cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practic...
- Late recurrence of basaloid carcinoma initially treated as a small cell lung Cancer.
- Phase 1 Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors.
- Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic Lung adenocarcinoma.
- Immune therapies for lung Cancer.
- Molecular classification of nonsmall-cell lung Cancer using a 4-protein quantitative assay.
- Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung Cancer.
- Novel chemotherapy options for advanced thyroid Tumors: small molecules offer great hope.
- High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas.
- Genotypic and histological evolution of lung Cancers acquiring resistance to EGFR inhibitors.
- HER-1, 2, and 3.
- Axitinib: The evidence of its potential in the treatment of advanced thyroid Cancer.
- Treatment of lung Cancer in older patients.
- Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung Cancer.
- A decade of advances in treatment for advanced non-small cell lung Cancer.
- High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage Lung adenocarcinoma.
- High expression of BCL-2 predicts favorable outcome in non-small cell lung Cancer patients with non squamous histology.
- Targeted therapy in advanced non-small-cell lung Cancer.
- Current status of vandetanib (ZD6474) in the treatment of non-small cell lung Cancer.
- Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid Tumors.
- Targeted therapy for thyroid Cancer: An updated review of investigational agents.
- Management of patients with advanced non-small cell lung Cancer: current and emerging options.
Schools
SUNY Dwnstate M C Coll Med
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Top Doctors: New York Metro Area
- CMS Meaningful Use Stage 1 Certification
Education
-
Mount Sinai Beth Israel -
State University of New York Downstate Medical Center College of Medicine
Hospital
-
Yale-New Haven Hospital
Drug Facts
| NPI NUMBER | 1477541274 | |
| NPPES Provider LastName | GETTINGER | |
| NPPES Provider FirstName | SCOTT | |
| NPPES Provider ZIPCode | 065191369 | |
| NPPES Provider State | CT | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 164.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1477541274 |
| Last Name Of The Provider | GETTINGER |
| First Name Of The Provider | SCOTT |
| View All |
Similar Doctors
|
|
Dr. Lyndsay N. Harris, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Thomas P. Duffy, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Peter McPhedran, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Maysa M. Abu-Khalaf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James M. Ziai, MD |
|
|
Dr. Irwin Nash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mario Sznol, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erkut Bahceci, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Iris Isufi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Caleb Ho, MD |
|
|
Dr. Marie E. Peddinghaus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gina G. Chung, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Karen E. Rabenau, MD |